Hormonal
GLP-1 receptor agonists show potential therapeutic benefits for psychiatric conditions, including depression, anxiety, binge-eating disorder, and substance use disorders, though evidence quality varies.
GLP-1 agonists may help with depression, anxiety, and binge-eating disorder, in addition to weight loss. However, results for addiction (like alcohol) are mixed. Consult a psychiatrist or physician to see if these medications might support your mental health treatment, especially if you have obesity or diabetes.
Vorläufige Untersuchungen weisen auf einen therapeutischen Nutzen von GLP-1-Rezeptoragonisten für Patientinnen und Patienten mit Demenz, Essstörungen, psychopharmakologisch induzierter Gewichtszunahme, Depressionen, Angststörungen und Abhängigkeitserkrankungen hin.
Why this rating
Evidence ranges from strong meta-analyses for depression to mixed/negative RCTs for alcohol dependence and unpublised cohort data for anxiety.
Source
Glucagon-like-peptide-1-Rezeptoragonisten: eine neue pharmakologische Behandlungsoption für psychiatrische Erkrankungen?
Hubertus Himmerich · Der Nervenarzt · 2025
DOI 10.1007/s00115-025-01813-x
More from this paper
- GLP-1 receptor agonists (e.g., liraglutide, semaglutide, tirzepatide) significantly reduce body weight and improve glycemic control in patients with Type 2 Diabetes and Obesity.Strong
- GLP-1 receptor agonists are associated with gastrointestinal side effects (nausea, vomiting, diarrhea) and potentially increased risks of pancreatitis and thyroid cancer.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →